cjm112
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Novartis PharmaceuticalsPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Novartis Pharmaceuticals | Phase 1 | CC |
gsk1120212 Novartis Pharmaceuticals | Phase 1 | CC |
Spartalizumab Novartis Pharmaceuticals | Phase 1 | CC |
egf816 Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
cjm112 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →